Detalhe da pesquisa
1.
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.
Thorax
; 78(6): 606-616, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35793833
2.
Characterization of human placenta-derived exosome (pExo) as a potential osteoarthritis disease modifying therapeutic.
Arthritis Res Ther
; 25(1): 229, 2023 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38017556
3.
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective.
J Med Econ
; 25(1): 160-171, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35037816
4.
Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England.
Clinicoecon Outcomes Res
; 14: 231-247, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35444434
5.
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 39(12): 1317-1328, 2021 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33621109